Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAD: Lanreotide Autogel Extended Interval in Acromegaly
NCT00701363Phase 4Completed
- Sponsor
- Ipsen
- Start
- Oct 2008
- Primary completion
- Mar 2013
- Modality
- Peptides
- Countries
- 14
01
Overview
A Phase 4 trial of lanreotide in acromegaly, sponsored by Ipsen. Started Oct 2008; status: completed.
02
Drugs
lanreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00701363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701363.